Linaclotide · Linzess, MD-1100

What is Linaclotide?

Linaclotide is a 14-amino acid peptide agonist of guanylate cyclase-C (GC-C) that increases intracellular and extracellular cyclic guanosine monophosphate (cGMP) in the intestinal epithelium. This activates the CFTR ion channel, promoting chloride and bicarbonate secretion into the intestinal lumen, accelerating GI transit and reducing intestinal pain.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Linzess, MD-1100, ASP-0456

Drug type

Peptide

Targets

guanylate cyclase-C (GUCY2C), cystic fibrosis transmembrane conductance regulator (CFTR) (secondary target)

Mechanism

Agonist of guanylate cyclase-C (GUCY2C)

Pathways

cGMP signaling, intestinal fluid secretion, GI transit acceleration

Therapy area

Gastroenterology

Developer

Abbvie

In trials of

IRWD

FDA status

Approved as Linzess (August 30, 2012), NDA202811 · FDA label

UNII

N0TXR0XR5X

✅ FDA-approved uses

• Irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older
• Chronic idiopathic constipation (CIC) in adults
• Functional constipation (FC) in pediatric patients 2 years of age and older

From the indications section of the FDA label (version of May 21, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic ConstipationConstipation

Other drugs acting on GUCY2C

Sources

• FDA label (DailyMed)
• FDA label Linzess (2026-05-21), indications
• NCI Thesaurus

Updated Oct 3, 2026.